Novo Nordisk Fails, Sanofi and Lilly Win

Shares of diabetes kingpin Novo Nordisk are down more than 10% to start the week after a weekend announcement that its new long-acting insulin products, Tresiba and Ryzodeg, were not approved by the Food and Drug Administration. Is this news really worth the $13 billion that investors have lopped off of the company's market cap this morning? In the following video, health care bureau chief Brenton Flynn runs through the story in more detail and discusses why Sanofi and Eli Lilly are the beneficiaries.

Should you swap from Novo Nordisk to Eli Lilly?
Very soon, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

The article Novo Nordisk Fails, Sanofi and Lilly Win originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.